Healthcare provider profile · identity verified

Todd A Miller, MD

Allopathic & Osteopathic Physicians|Family Medicine · HARTLAND, WI · NPI 1952352486

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Todd A Miller, MD received $37.54 in general payments during 2025 across 2 reported records.

Novo Nordisk Inc accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$37.54

2 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$37.54	100.0%	2	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$37.54	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
Ozempic Normalized: ozempic	Drug	Novo Nordisk Inc	$37.54	2	2025
Source payment records 2025-05-08 · Novo Nordisk Inc · $20.40 · Open Payments source 2025-07-17 · Novo Nordisk Inc · $17.14 · Open Payments source
Rybelsus Normalized: rybelsus	Drug	Novo Nordisk Inc	$37.54	2	2025
Source payment records 2025-05-08 · Novo Nordisk Inc · $20.40 · Open Payments source 2025-07-17 · Novo Nordisk Inc · $17.14 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
Ozempic ozempic	2025	Ozempic	2024	16 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Ozempic open payments reported associated product	CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076	Ozempic · 2024 Exact normalized brand match · 1 Part D row	16	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	584	145
Amlodipine Besylate	Amlodipine Besylate	519	126
Levothyroxine Sodium	Levothyroxine Sodium	492	123
Losartan Potassium	Losartan Potassium	434	118
Pantoprazole Sodium	Pantoprazole Sodium	376	100
Gabapentin	Gabapentin	354	76
Metoprolol Succinate	Metoprolol Succinate	313	76
Lisinopril	Lisinopril	284	74
Simvastatin	Simvastatin	261	68
Rosuvastatin Calcium	Rosuvastatin Calcium	252	66
Hydrochlorothiazide	Hydrochlorothiazide	238	63
Tramadol Hcl	Tramadol Hcl	230	40
Omeprazole	Omeprazole	209	57
Furosemide	Furosemide	208	53
Tamsulosin Hcl	Tamsulosin Hcl	196	49
Allopurinol	Allopurinol	183	45
Pravastatin Sodium	Pravastatin Sodium	166	44
Trazodone Hcl	Trazodone Hcl	161	31
Clopidogrel	Clopidogrel Bisulfate	160	38
Eliquis	Apixaban	150	32
Potassium Chloride	Potassium Chloride	149	35
Metformin Hcl Er	Metformin Hcl	135	35
Metoprolol Tartrate	Metoprolol Tartrate	133	40
Benazepril Hcl	Benazepril Hcl	132	33
Zolpidem Tartrate	Zolpidem Tartrate	125	28
Glimepiride	Glimepiride	119	28
Jardiance	Empagliflozin	116	22
Prednisone	Prednisone	111	28
Escitalopram Oxalate	Escitalopram Oxalate	110	25
Lorazepam	Lorazepam	109	27
Albuterol Sulfate Hfa	Albuterol Sulfate	108	48
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	106	19
Meloxicam	Meloxicam	104	32
Finasteride	Finasteride	103	19
Duloxetine Hcl	Duloxetine Hcl	101	16
Carvedilol	Carvedilol	100	26
Irbesartan	Irbesartan	96	28
Pregabalin	Pregabalin	96	16
Sertraline Hcl	Sertraline Hcl	96	25
Metformin Hcl	Metformin Hcl	94	28
Alprazolam	Alprazolam	92	25
Atenolol	Atenolol	90	20
Spironolactone	Spironolactone	88	26
Bupropion Xl	Bupropion Hcl	85	16
Ezetimibe	Ezetimibe	81	17
Tizanidine Hcl	Tizanidine Hcl	81	25
Fluoxetine Hcl	Fluoxetine Hcl	77	15
Montelukast Sodium	Montelukast Sodium	70	17
Donepezil Hcl	Donepezil Hcl	69	12
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	69	16
Warfarin Sodium	Warfarin Sodium	69	16
Clonazepam	Clonazepam	68	16
Citalopram Hbr	Citalopram Hydrobromide	64	19
Synthroid	Levothyroxine Sodium	61	13
Fenofibrate	Fenofibrate	59	14
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	59	16
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	57	12
Xarelto	Rivaroxaban	57	suppressed
Fluticasone Propionate	Fluticasone Propionate	56	24
Azithromycin	Azithromycin	54	46
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	53	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	53	14
Famotidine	Famotidine	48	13
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	48	13
Nifedipine Er	Nifedipine	48	12
Quetiapine Fumarate	Quetiapine Fumarate	48	13
Alfuzosin Hcl Er	Alfuzosin Hcl	46	14
Venlafaxine Hcl Er	Venlafaxine Hcl	46	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	45	suppressed
Mirtazapine	Mirtazapine	44	suppressed
Celecoxib	Celecoxib	42	12
Clonidine Hcl	Clonidine Hcl	41	12
Diclofenac Sodium	Diclofenac Sodium	40	14
Diazepam	Diazepam	39	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	38	suppressed
Amoxicillin	Amoxicillin	37	26
Lamotrigine	Lamotrigine	37	suppressed
Aripiprazole	Aripiprazole	36	suppressed
Alendronate Sodium	Alendronate Sodium	35	11
Baclofen	Baclofen	35	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	35	11
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	34	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	33	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	33	22
Memantine Hcl	Memantine Hcl	32	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	32	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	32	25
Hydralazine Hcl	Hydralazine Hcl	31	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	31	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	30	suppressed
Buspirone Hcl	Buspirone Hcl	29	suppressed
Ondansetron Hcl	Ondansetron Hcl	29	suppressed
Propranolol Hcl	Propranolol Hcl	29	suppressed
Januvia	Sitagliptin Phosphate	28	suppressed
Trulicity	Dulaglutide	28	suppressed
Myrbetriq	Mirabegron	27	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	26	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	26	suppressed
Telmisartan	Telmisartan	26	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	25	12
Temazepam	Temazepam	25	suppressed
Propranolol Hcl Er	Propranolol Hcl	23	suppressed
Amiodarone Hcl	Amiodarone Hcl	22	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	22	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	21	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	21	14
Ropinirole Hcl	Ropinirole Hcl	21	suppressed
Spiriva Respimat	Tiotropium Bromide	21	suppressed
Cephalexin	Cephalexin	20	17
Dextroamphetamine Sulfate Er	Dextroamphetamine Sulfate	20	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	20	18
Tradjenta	Linagliptin	20	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	19	suppressed
Breo Ellipta	Fluticasone/Vilanterol	19	suppressed
Chlorthalidone	Chlorthalidone	19	suppressed
Methadone Hcl	Methadone Hcl	19	suppressed
Methylprednisolone	Methylprednisolone	19	16
Nystatin	Nystatin	19	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	19	17
Valacyclovir	Valacyclovir Hcl	19	suppressed
Meclizine Hcl	Meclizine Hcl	18	suppressed
Ondansetron Odt	Ondansetron	18	suppressed
Benazepril-Hydrochlorothiazide	Benazepril/Hydrochlorothiazide	17	suppressed
Glipizide	Glipizide	17	suppressed
Glipizide Er	Glipizide	17	suppressed
Lactulose	Lactulose	17	suppressed
Lansoprazole	Lansoprazole	17	suppressed
Nebivolol Hcl	Nebivolol Hcl	17	suppressed
Torsemide	Torsemide	17	suppressed
Valsartan	Valsartan	17	suppressed
Verapamil Er	Verapamil Hcl	17	suppressed
Ozempic	Semaglutide	16	suppressed
Rabeprazole Sodium	Rabeprazole Sodium	16	suppressed
Ventolin Hfa	Albuterol Sulfate	16	suppressed
Oxycodone Hcl	Oxycodone Hcl	15	suppressed
Acetazolamide	Acetazolamide	14	suppressed
Zaleplon	Zaleplon	14	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	13	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	13	12
Divalproex Sodium Er	Divalproex Sodium	13	suppressed
Eszopiclone	Eszopiclone	13	suppressed
Memantine Hcl Er	Memantine Hcl	13	suppressed
Nitroglycerin	Nitroglycerin	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Solifenacin Succinate	Solifenacin Succinate	13	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	13	suppressed
Cefuroxime	Cefuroxime Axetil	12	12
Cholestyramine Light	Cholestyramine	12	suppressed
Diltiazem 24hr Er (Xr)	Diltiazem Hcl	12	suppressed
Folic Acid	Folic Acid	12	suppressed
Methocarbamol	Methocarbamol	12	suppressed
Potassium Citrate Er	Potassium Citrate	12	suppressed
Primidone	Primidone	12	suppressed
Ramelteon	Ramelteon	12	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	12	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	12	suppressed
Belsomra	Suvorexant	11	suppressed
Epinephrine	Epinephrine	11	suppressed
Lurasidone Hcl	Lurasidone Hcl	11	suppressed
Methylphenidate Hcl Er (Cd)	Methylphenidate Hcl	11	suppressed
Ramipril	Ramipril	11	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	11	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$37.54 · 2 records	Novo Nordisk Inc	Ozempic, Rybelsus	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Ozempic play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error